TransMedics Group is trading at $87.28, up +4.04%, driven by record quarterly revenue and higher 2026 guidance.
- Shares are extending their rebound after August 7, 2026, when they closed at $83.89.
- Second-quarter revenue reached approximately $189.9 million; 2026 revenue guidance rose to $737 million-$757 million, while margin guidance was reduced to 12.5%-14%.
- The broader healthcare sector strengthened, but mixed major indexes suggest company-specific earnings optimism is the primary catalyst.